US 12,239,667 B2
Extracellular vesicles isolated from genetically modified cells over-expressing SERPINB3 for use in medicine
Patrizia Pontisso, Padua (IT); Maurizio Muraca, Padua (IT); Alessandra Biasiolo, Selvazzano Dentro (IT); Santina Quarta, Villaguattera di Rubano (IT); Mariagrazia Ruvoletto, Vigonovo (IT); and Gianmarco Villano, Padua (IT)
Assigned to UNIVERSITÀ DEGLI STUDI DI PADOVA, Padua (IT)
Appl. No. 17/430,739
Filed by UNIVERSITA' DEGLI STUDI DI PADOVA, Padua (IT)
PCT Filed Feb. 14, 2020, PCT No. PCT/IB2020/051244
§ 371(c)(1), (2) Date Aug. 13, 2021,
PCT Pub. No. WO2020/165851, PCT Pub. Date Aug. 20, 2020.
Claims priority of application No. 102019000002155 (IT), filed on Feb. 14, 2019.
Prior Publication US 2022/0143098 A1, May 12, 2022
Int. Cl. A61K 35/28 (2015.01); A01N 1/02 (2006.01)
CPC A61K 35/28 (2013.01) [A01N 1/0226 (2013.01)] 14 Claims
 
1. A method of using extracellular vesicles isolated from a cell line over-expressing SerpinB3 in subjects in need thereof, comprising:
administering to said subjects an effective amount of said extracellular vesicles,
wherein said vesicles are isolated from genetically modified cells over-expressing SerpinB3, and
wherein a concentration of said SerpinB3 in said extracellular vesicles is increased relative to extracellular vesicles isolated from a cell line that does not overexpress SerpinB3.